Cara Therapeutics, Inc. (NASDAQ:CARA) has reserved a top momentum style rating from Zacks Research. The momentum rating acts as an important barometer to show as to when a stock will attain a favourable position, which will provide a window of opportunity to benefit from equity movement in either direction. Momentum traders often study the price swings of a stock and draw opinion that the stock will move in a particular direction, yielding a profitable trade. The momentum strategy aims to provide a short-term forecast about the stock price movements over fundamental stock analysis and is being taken into account by experienced traders only.
Over and above the momentum score, Investors considering investing in Cara Therapeutics, Inc. (NASDAQ:CARA) can also take into account past earnings track record and future brokerage recommendations. As per Zacks, Cara Therapeutics, Inc. has been assigned a mean rating of 1. Such mean rating is based on a simplified scale of 1-5, where number one denotes a Strong Buy and number five is a Strong Sell. The consensus market rating signifies the individual rating of each brokerage analysts covering the stock.
The one-year price estimate of the Cara Therapeutics, Inc. (NASDAQ:CARA) stands at $23.5 as per the brokerage firms. The price estimate shows the average recommendations of a total of 4 analysts provided in the last six months. The most bullish price estimate of the stock is set at $28 while the bearish estimate is kept at $18 over the next one year.
As Cara Therapeutics, Inc. is slated to release its earnings on or around 2016-05-10, the brokerage firms are anticipating it to report earnings of -0.41. In its most last quarter for the period ended on 2015-12-31, the company posted earnings per share of $-0.35.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...